These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 4707864)

  • 21. [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
    Trier H; Rønne T
    Ugeskr Laeger; 1992 Jul; 154(29):2008-13. PubMed ID: 1509566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
    Bhargava I; Chhaparwal BC; Phadke MA; Irani SF; Chhaparwal D; Dhorje S; Maheshwari CP
    Indian Pediatr; 1995 Sep; 32(9):983-8. PubMed ID: 8935261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A field trial of combined measles-mumps-rubella vaccine. Satisfactory immunization with 188 children in Chile.
    Borgoño JM; Greiber R; Solari G; Concha F; Carrillo B; Hilleman MR
    Clin Pediatr (Phila); 1973 Mar; 12(3):170-2. PubMed ID: 4701464
    [No Abstract]   [Full Text] [Related]  

  • 24. Measles, mumps, and rubella vaccine: time for a two stage policy.
    Sloan DS
    BMJ; 1992 Apr; 304(6831):916. PubMed ID: 1392776
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mumps epidemic in vaccinated children in West Switzerland].
    Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D
    Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial.
    Swartz TA; Klingberg W; Klingberg MA
    Infection; 1974; 2(3):115-7. PubMed ID: 4606362
    [No Abstract]   [Full Text] [Related]  

  • 27. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine.
    Beck M; Smerdel S; Dedić I; Delimar N; Rajninger-Miholic M; Juzbasić M; Manhalter T; Vlatković R; Borcić B; Mihajić Z
    Dev Biol Stand; 1986; 65():95-100. PubMed ID: 3556780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1975 Sep; 56(3):380-7. PubMed ID: 1161394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunity against measles and rubella in Massachusetts schoolchildren.
    Orenstein WA; Herrmann K; Albrecht P; Bernier R; Holmgreen P; Bart KJ; Hinman AR
    Dev Biol Stand; 1986; 65():75-83. PubMed ID: 3556779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of rubella during an epidemic on Taiwan. HPV-77 and RA 27-3 rubella vaccines administered subcutaneously and intranasally HPV-77 vaccine mixed with mumps and-or measles vaccines.
    Beasley RP; Detels R; Kim KS; Gale JL; Lin TL; Grayston JT
    Am J Dis Child; 1969 Aug; 118(2):301-6. PubMed ID: 4893832
    [No Abstract]   [Full Text] [Related]  

  • 31. [Simultaneous administration at different dosages of attenuated live virus vaccines against measles, mumps and rubella].
    Ramos-Alvarez M; Bessudo L; Kenny MT; Jackson JE; Schwarz AJ
    Bol Med Hosp Infant Mex; 1976; 33(4):875-86. PubMed ID: 782484
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ; Robertson PW; Whybin LR
    Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic.
    Ehrenkranz NJ; Ventura AK; Medler EM; Jackson JE; Kenny MT
    Bull World Health Organ; 1975; 52(1):81-5. PubMed ID: 764997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administration of live virus vaccines to a child with recent infectious mononucleosis.
    Sumaya C
    Pediatr Infect Dis J; 1991 Oct; 10(10):790-1. PubMed ID: 1945588
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
    André FE; Peetermans J
    Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination.
    Lerman SJ; Bollinger M; Brunken JM
    Pediatrics; 1981 Jul; 68(1):18-22. PubMed ID: 7017582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The measles-mumps-rubella vaccination program in Finland.
    Redd SC; Wharton M; Hadler SC; Orenstein WA
    N Engl J Med; 1995 Apr; 332(16):1102-3. PubMed ID: 7898540
    [No Abstract]   [Full Text] [Related]  

  • 39. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
    Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE
    Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.